Lyell Immunopharma, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2026 Annual Meeting of Stockholders held virtually on June 10, 2026. The meeting addressed three proposals: the election of Class II directors, the ratification of the independent auditor, and an advisory vote on executive compensation.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Stockholders representing 67.31% of outstanding shares (15,706,826 shares) participated in the meeting. All three proposals were approved:
- Proposal 1 (Election of Directors): Richard Klausner, M.D., Otis Brawley, M.D., and William Rieflin were elected to serve until the 2029 annual meeting. Significant broker non-votes (3,429,286) were recorded for this proposal.
- Proposal 2 (Auditor Ratification): Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 15,674,347 votes for and 30,758 votes against.
- Proposal 3 (Executive Compensation): The advisory vote on named executive officer compensation was approved with 11,860,218 votes for and 6,613 votes against.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on business outlook, specific risks, contingencies, or unusual items. The document serves solely to disclose the certified voting results.
Investor Verification Checklist
- Verify the definitive proxy statement (Schedule 14A) filed on April 24, 2026, for detailed biographies of the elected directors and full compensation disclosures.
- Confirm the total number of shares outstanding (23,332,254) as of the April 14, 2026 record date.
- Review the high volume of broker non-votes (3,429,286) on the director election and executive compensation proposals to understand voting power distribution.